Javier Mar
Overview
Explore the profile of Javier Mar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
123
Citations
1060
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Estadilla C, Cicolani C, Blasco-Aguado R, Saldana F, Borri A, Mar J, et al.
BMC Public Health
. 2025 Mar;
25(1):1004.
PMID: 40087626
Background: In response to the rapid global transmission of COVID-19, governments worldwide enacted lockdowns and other non-pharmaceutical interventions (NPI) to control the disease. In this study, we aim to quantify...
2.
Gorostiza I, Bilbao-Gonzalez A, Mar J
Gac Sanit
. 2025 Feb;
:102451.
PMID: 39971633
Objective: There is evidence on the efficiency of new direct oral anticoagulants (DOAC), mostly based on experimental efficacy data, but there is also a need to assess their cost-effectiveness in...
3.
Cruces-Salguero S, Sol J, Larranaga I, Pamplona R, Mar J, Jove M, et al.
Geroscience
. 2025 Jan;
PMID: 39809916
Disability and multimorbidity increase with aging and constitute a challenge for the health system. However, different individuals display different aging trajectories, and understanding the underlying relationships between lifespan and disease...
4.
Zumeta-Olaskoaga L, Ibarrondo O, Del Pozo R, Zapiain A, Larranaga I, Mar J
Value Health
. 2024 Dec;
PMID: 39733834
Objectives: To estimate the excess formal social costs or direct non-healthcare costs of dementia-related neuropsychiatric symptoms (NPS). Methods: The presence of dementia, NPS, antipsychotic and antidepressant use, somatic and psychiatric...
5.
Cruces-Salguero S, Larranaga I, Mar J, Matheu A
Aging Clin Exp Res
. 2024 Nov;
36(1):228.
PMID: 39612148
Background: The COVID-19 pandemic impacted worldwide. The Basque Country was one of the regions in Spain most affected by the virus. Methods: In this retrospective study, we took advantage of...
6.
Srivastav A, Stollenwerk N, Van-Dierdonck J, Mar J, Ibarrondo O, Aguiar M
PLoS One
. 2024 Nov;
19(11):e0314214.
PMID: 39541375
[This corrects the article DOI: 10.1371/journal.pone.0267772.].
7.
Cruces-Salguero S, Larranaga I, Mar J, Matheu A
Geroscience
. 2024 Nov;
PMID: 39520650
Cancer is one of the leading causes of death and its prevalence increases with age. While centenarians exhibit extreme longevity and potential to avoid or delay aging-related diseases, their response...
8.
Handels R, Herring W, Kamgar F, Aye S, Tate A, Green C, et al.
Value Health
. 2024 Oct;
PMID: 39384068
Objectives: Decision-analytic models assessing the value of emerging Alzheimer's disease (AD) treatments are challenged by limited evidence on short-term trial outcomes and uncertainty in extrapolating long-term patient-relevant outcomes. To improve...
9.
Estadilla C, Mar J, Ibarrondo O, Stollenwerk N, Aguiar M
J Epidemiol Glob Health
. 2024 Aug;
14(3):1289-1299.
PMID: 39186212
COVID-19 vaccines have demonstrated significant efficacy in reducing severe symptoms and fatalities, although their effectiveness in preventing transmission varies depending on the population's age profile and the dominant variant. This...
10.
Mar J, Zubiagirre U, Larranaga I, Soto-Gordoa M, Mar-Barrutia L, Gonzalez-Pinto A, et al.
J Alzheimers Dis
. 2024 Jun;
100(2):645-655.
PMID: 38943388
Background: Antipsychotics are widely used in the elderly due to the high prevalence of neuropsychiatric associated with dementia. Objective: To analyze potential disparities in antipsychotic use in the general population...